BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, Johanna Estrada et al.|Cancer Cell|2014Cited by 366
Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based studyAytug Kizilors, Hugues de Lavallade, Elena Crisà et al.|The Lancet Haematology|2019Cited by 56